English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Momordica charantia  (bitter gourd) has been used in the traditional system of medicine for the treatment of various diseases. Anticancer activity of  M. charantia  extracts has been demonstrated by numerous  in vitro  and  in vivo  studies. In the present study, we investigated the differentiation inducing potential of fractionated  M. charantia  seed extracts in human myeloid HL60 cells. We found that the HL60 cells treated with the fractionated seed extracts differentiated into granulocytic lineage as characterized by NBT staining, CD11b expression, and specific esterase activity. The differentiation inducing principle was found to be heat-stable, and organic in nature. The differentiation was accompanied by a downregulation of  c-myc  transcript, indicating the involvement of  c-myc  pathway, at least in part, in differentiation. Taken together these results indicate that fractionated extracts of  M. charantia  seeds possess differentiation inducing activity and therefore can be evaluated for their potential use in differentiation therapy for leukemia in combination with other inducers of differentiation.

Antileukemic Potential ofMomordica charantiaSeed Extracts on Human Myeloid Leukemic HL60 Cells